Diversity and evolution of the DRB1*03 family: Description of DRB1*03022, *0307, *0308

Tissue Antigens

Volumn 49, Issue 1, 1997, Pages 41-45

  Ellis, J M ^a   Steiner, N ^a   Wang, J ^a,b   Tang, T T ^a,b   Hurley, C K ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

DR3; Evolution; Gene conversion; Human leukocyte antigen (HLA)

Indexed keywords

GLUTAMIC ACID; HLA DR ANTIGEN; PHENYLALANINE; TYROSINE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BIODIVERSITY; CODON; EVOLUTION; GENE CONVERSION; HUMAN; HUMAN CELL; IMMUNOGENETICS; MULTIGENE FAMILY; PRIORITY JOURNAL;

EID: 33744978613     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1997.tb02708.x     Document Type: Article

References (18)

1. Stern LJ, Brown JH, Jardetzky TS et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994: 368: 215-21.
2. Barber LD, Parham P. Peptide binding to major histocompatibility complex molecules. Annu Rev Cell Biol 1993: 9: 163-206.
3. Madden DR. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol 1995: 13: 587-622.
4. Bodmer JG, Marsh SGE, Albert ED et al. Nomenclature for factors of the HLA system, 1995. Tissue Antigens 1995: 46: 1-18.
5. Hughes AL, Hughes MK. Natural selection on the peptide-binding regions of major histocompatibility complex molecules. Immunogenetics 1995: 42: 233-43.
6. Parham P, Ohta T. Population biology of antigen presentation by MHC Class I molecules. Science 1996: 272: 67-74.
7. Bodmer JG, Marsh SGE, Albert ED et al. Nomenclature for factors of the HLA system, 1991. Tissue Antigens 1992: 39: 161-73.
8. Posch PE, Araujo HA, Cresswell K, Praud C, Johnson A, Hurley CK. Microvariation creates significant functional differences in the DR3 molecules. Hum Immunol 1995: 42: 61-72.
9. Posch PE, Hurley CK, Geluk A, Ottenhoff THM. The impact of DR3 microvariation on peptide binding: the combinations of specific DRβ residues critical to binding differ for different peptides. Hum Immunol 1996: 49: 96-105.
10. Shaffer AL, Falk-Wade JA, Tortorelli V et al. HLA-DRw52-associated DRB1 alleles: identification using polymerase chain reaction-amplified DNA, sequence-specific oligonucleotide probes, and a chemiluminescent detection system. Tissue Antigens 1992: 39: 84-90.
11. Kimura A, Dong RP, Harada H, Sasazuki T. DNA typing of HLA class II genes in B-lymphoblastoid cell lines homozygous for HLA. Tissue Antigens 1992: 40: 5-12.
12. Marsh SGE, Bodmer JG. HLA Class II region nucleotide sequences, 1995. Tissue Antigens 1995: 46: 258-80.
13. Rodriguez SG, Crevling CL, Steiner N, Hurley CK. Identification of a new allele, DRB1*1204, during routine PCR-SSOP typing of National Marrow Donor Program volunteers. Tissue Antigens 1996: 48: 221-23.
14. Geluk A, Elferink DG, Slierendregt BL et al. Evolutionary conservation of major histocompatibility complex-DR/peptide/T cell interactions in primates. J Exp Med 1993: 177: 979-87.
15. Erlich HA, Gyllensten UB. Shared epitopes among HLA class II alleles: gene conversion, common ancestry and balancing selection. Immunol Today 1991: 12: 411-4.
16. Eberle M, Baxter-Lowe LA. A silent mutation in HLA-DRB1*0301 can affect oligotyping. Tissue Antigens 1992: 40: 150-2.
17. Hurley CK, Steiner N. Differences in peptide binding of DR11 and DR13 microvariants demonstrate the power of minor variation on DR functional diversity. Hum Immunol 1995: 43: 101-12.
18. Klohe E, Pistillo MP, Ferrara GB, Goeken NE, Greazel NS, Karr RW. Critical role of HLA-DRβ1 residue 58 in multiple polymorphic epitopes recognized by xenogeneic and allogeneic antibodies. Hum Immunol 1992: 35: 18-28.